Skip to main content

Regulatory and Washington

  • Watson appoints former GPhA executive as VP government affairs

    PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has hired a former executive from the Generic Pharmaceutical Association to head lobbying at the federal and state level, the company said Wednesday.

    Watson announced the appointment of James Fenton as VP U.S. government affairs. In the new position, Fenton will work out of Watson's Washington offices and will be responsible for leading the company's expanded federal and state government affairs activities.

  • FDA advises consumers not to purchase adulterated 'MAXILOSS Weight Advanced'

    SILVER SPRING, Md. — The Food and Drug Administration on Tuesday advised consumers not to purchase or use “MAXILOSS Weight Advanced” — a product promoted and sold for weight loss on various web sites, including DreamLifeWeightLoss.com, and in some retail stores.

  • ERSP requests Casper Labs to tone down marketing message behind supplement Calmestra

    NEW YORK — The Electronic Retailing Self-Regulation Program on Tuesday recommended that Casper Labs modify or discontinue certain claims for Calmestra, a dietary supplement marketed as providing relief for symptoms of menopause, including claims that the product has been “clinically proven” to address symptoms of menopause.

  • Use of generics would save money, study finds

    WASHINGTON — A new study indicates that the public bears "unnecessary expense" when generic drugs aren't used.

  • Vitamin Shoppe proposed acquisition of Super Supplements delayed

    NORTH BERGEN, N.J. — The Vitamin Shoppe's proposed acquisition of Super Supplements has been delayed, the company recently announced. According to the company, the Federal Trade Commission had notified VSI that it is conducting an investigation into the planned acquisition, noting that the investigation will extend beyond Dec. 31, 2012.

  • Biotech regulatory environment has improved, report finds

    SAN FRANCISCO — Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.

    The 2013 California Biomedical Industry Report — by PwC, the California Healthcare Institute and BayBio — looked at California's biotech industry and how it faired in 2012.

  • Campaign seeks to raise awareness of inflammatory bowel disease

    NEW YORK — An organization focused on inflammatory bowel disease has enlisted a star of "NYPD Blue," "Judging Amy" and "Private Practice" to raise awareness of the condition.

    The Crohn's and Colitis Foundation of America hired actress Amy Brenneman, who has ulcerative colitis, one of two diseases that collectively make up IBD; the other is Crohn's disease. Both conditions are autoimmune diseases that cause discomfort and inflammation of the intestines and require frequent trips to the bathroom.

  • Mass. governor proposes new compounding pharmacy legislation

    BOSTON — Massachusetts Gov. Deval Patrick has introduced legislation that would give the state government broader power over compounding pharmacies, the governor's office announced.

X
This ad will auto-close in 10 seconds